Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Cash from Financing Activities for 10 consecutive years, with -$43.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 256.47% year-over-year to -$43.1 million, compared with a TTM value of -$132.6 million through Dec 2025, down 204.38%, and an annual FY2025 reading of -$132.6 million, down 204.38% over the prior year.
  • Cash from Financing Activities was -$43.1 million for Q4 2025 at Anaptysbio, down from -$10.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $251.3 million in Q4 2021 and bottomed at -$50.5 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $11.6 million, with a median of $204000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 199373.02% in 2021, then plummeted 3223.15% in 2023.
  • Year by year, Cash from Financing Activities stood at $251.3 million in 2021, then crashed by 99.22% to $1.9 million in 2022, then tumbled by 364.7% to -$5.2 million in 2023, then skyrocketed by 634.35% to $27.6 million in 2024, then tumbled by 256.47% to -$43.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ANAB at -$43.1 million in Q4 2025, -$10.4 million in Q3 2025, and -$50.5 million in Q2 2025.